The medical technology sector experienced a dramatic year of contrasts, according to EY's 2026 Pulse of the Industry report. While M&A activity soared to its highest level in over a decade at approximately $130 billion, the industry simultaneously grappled with declining valuations, lowered growth forecasts, and intensifying competition for capital from AI investments.

Record M&A Activity Masks Underlying Challenges

Total disclosed medtech M&A deal value reached approximately $130 billion in the twelve months ending June 30, 2026—more than triple the $39 billion recorded in the prior year period. However, this surge was driven primarily by four mega-deals exceeding $10 billion each, rather than broad-based industry strength.

The blockbuster transactions included Waters' $17.5 billion purchase of BD's biosciences and diagnostic solutions division in February, Abbott's $21 billion acquisition of Exact Sciences in March, Danaher's $9.9 billion buy of Masimo in June, and Boston Scientific's pending $15.2 billion acquisition of Penumbra.

Despite this dealmaking frenzy, medtech company valuations declined nearly 10% in the first half of 2026 compared to the year-ago period, with total market capitalization standing at $1.58 trillion. Major players including Boston Scientific and Abbott lowered their sales growth forecasts for 2026, signaling headwinds ahead.

Private Equity and Spinoffs Reshape the Landscape

Private equity firms have become increasingly active participants in medtech deals, with GTCR, Patient Square Capital, and American Industrial Partners among the notable players. Meanwhile, a spinoff trend continues to reshape corporate portfolios as companies seek to streamline operations and unlock shareholder value.

Medtronic's diabetes unit MiniMed went public in March 2026, while Johnson & Johnson is planning an orthopedic unit spinoff or divestiture. Abbott has announced plans to shed its nutrition business, reflecting a broader industry movement toward focused specialization.

Capital raised in the first half of 2026 was primarily fueled by debt due to the large dealmaking activity, though venture funding remained robust despite market challenges.

Investor Focus Shifts to Robotics and Procedure-Based Treatments

According to the report, investor interest has concentrated in specific technology areas including robotics, brain-computer interfaces, and procedure-based alternatives to pharmaceutical treatments. The latter category encompasses innovations such as renal denervation for hypertension and tumor ablation for cancer treatment.

This shift toward procedure-based interventions creates new opportunities for AI-enhanced technologies in procedural guidance, outcome prediction, and patient selection algorithms. However, EY Global MedTech Leader John Babitt expects decelerating growth at the end of 2026, suggesting the industry faces continued pressure to demonstrate clear returns on investment.

The consolidation wave and valuation pressures indicate that medtech companies will likely prioritize AI investments that show demonstrable clinical efficacy and financial returns, rather than pursuing speculative technology development. For health AI startups, this environment presents both challenges and opportunities as larger players seek to integrate advanced capabilities into their diagnostic, monitoring, and therapeutic platforms.

Sources

  1. 3 highlights from EY's report on 2026 medtech trends — MedTech Dive